H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $15 and keeps a Buy rating on the shares. The FDA signaled that Nex-Z’s clinical risk is manageable by lifting the clinical hold, but the market is still pricing in “an existential threat,” the analyst tells investors in a research note. The firm upped its probability of approval to 35% from 25%.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Citizens says nex-z return to clinic should add ‘significant value’ to Intellia
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Safety Freeze on Nerve Disease Trial
- Intellia up 24% in premarket at $17.34 as FDA lifts hold on nex-z Phase 3 study
- FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial